Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Collaborates with Takeda on Hypertension Drug Discovery

NEW YORK, July 27 (GenomeWeb News) - Lexicon Genetics today announced it will collaborate with Takeda to develop new drugs for the treatment of high blood pressure.

 

Under the terms of the agreement, Takeda will have exclusive access to all drug targets that control blood pressure from Lexicon's Genome5000 program. Takeda will be responsible for screening, medicinal chemistry, preclinical and clinical development, and commercialization of drugs directed against Lexicon's targets, the company said.

 

Lexicon will receive an upfront payment of $12 million from Takeda for the initial, three-year term of the agreement. Takeda will have the option of extending the discovery portion of the alliance for an additional two years in exchange for further committed funding, Lexicon said. Lexicon will also earn royalties on worldwide sales of drugs commercialized by Takeda.

 

In the Genome5000 program, Lexicon is using gene knockout technology to discover the function of 5,000 of the most pharmaceutically important genes in the human genome, the company said.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.